Nutraceutical Interventions in Stunting: Advances, Challenges, and Prospects
This narrative review maps molecular and genetic mechanisms of stunting and surveys emerging nutraceutical interventions, but does not establish causal evidence of efficacy for any specific nutraceutical.
| Endpunkt | Grad | Richtung | Effekt | Studien |
|---|---|---|---|---|
| Linear growth (HAZ) | C | — Neutral | Heterogeneo; sem pooled effect size reportado | — |
| GH–IGF-1 signaling | D | — Unzureichend | Mecanismo proposto; sem dados de intervenção controlada | — |
| SOCS3 methylation and growth | C | — Unzureichend | Associação observacional; sem IC reportado | — |
| Environmental enteric dysfunction (EED) and intestinal permeability | C | — Unzureichend | Dados mecanísticos sem intervenção nutraceutica controlada | — |
| Gut microbiome composition | D | — Unzureichend | Padrões em caracterização; sem efeito de intervenção quantificado | — |
| Cognitive and neurodevelopmental outcomes | D | — Unzureichend | Mencionado como consequência do nanismo; sem dados de intervenção | — |
| Stunting prevalence with MNPs/LNS | B | ▲ Günstig | Reducao reportada em revisoes citadas; heterogeneidade alta; sem IC proprio | — |
Kontext
An estimated 149.2 million children under 5 were affected by stunting in 2020, with prevalence exceeding 30% in low- and middle-income countries (LMICs). Conventional nutritional interventions yield limited and heterogeneous linear growth gains. Nutraceuticals such as bioactive peptides, phytochemicals, and next-generation probiotics emerge as adjunctive candidates but lack robust clinical trials in this population.
Was die Studie zeigte
The narrative review performs no original meta-analysis and presents no pooled data with 95% CI or original effect sizes. Cited systematic reviews indicate that MNPs, LNS, and food fortification reduce stunting prevalence, but consistent improvements in linear growth are limited and highly heterogeneous. Epigenetic mechanisms (SOCS3 methylation, H3K27 acetylation, H3K9 trimethylation) and miRNAs (miR-21, miR-122) are identified as GH–IGF-1 axis regulators without controlled intervention data. No emerging nutraceutical has demonstrated proven efficacy on linear growth outcomes in high-quality clinical trials in the target population.
Wie es durchgeführt wurde
Narrative review. Searches in PubMed, Scopus, and Web of Science using Boolean combinations of terms including 'nutraceuticals AND stunting' and 'dietary interventions AND linear growth'. Selection based on relevance and perceived quality; no registered protocol, no systematic data extraction, no formal risk-of-bias tool applied.
Effektgröße
No original effect sizes with 95% CI are calculated or reported by the authors. Cited primary studies show high heterogeneity and effects on linear growth classified as limited.
Einschränkungen
Narrative design without a registered protocol precludes replication and introduces selection and publication bias. No quality assessment tool (AMSTAR-2, RoB 2, ROBINS-I) was applied to included studies. The review covers molecular mechanisms not clinically tested in stunting populations, limiting causal inference. Absence of data disaggregated by geographic context, age group, or nutritional phenotype reduces direct applicability.
In der klinischen Praxis
Insufficient evidence to recommend emerging nutraceuticals (bioactive peptides, phytochemicals, next-generation probiotics) as replacements or adjuncts to established stunting interventions. Practitioners should maintain protocols based on MNPs, LNS, and correction of specific deficiencies per WHO/UNICEF guidelines. Assessment of intestinal inflammatory status and barrier function may guide future precision strategies but remains outside routine clinical practice in LMICs.
Was noch fehlt
Adequately powered, registered RCTs conducted in high-burden LMICs evaluating specific nutraceuticals (probiotics, bioactive peptides) with linear growth as the primary outcome. Longitudinal multi-omics studies are needed to translate epigenetic and microbiome findings into validated therapeutic targets.